As President, Strange worked towards refocusing the MDI Biological Laboratory's research program and recruiting multidisciplinary scientists to understand the genetic mechanisms of tissue repair, regeneration, and aging.
[1] Strange was an associate professor at Harvard Medical School and director of the critical care research laboratories at Children's Hospital in Boston.
[1] In 2013, Strange founded the MDI Biological Laboratory's first spinout company, Revidia Therapeutics, Inc., to accelerate the testing and development of a novel drug candidate for patients with heart disease.
[2] That year, the magazine Mainebiz named Strange one of Maine's ten most “innovative business people” who “hold tremendous promise for the state” and its future economy.
[3] Strange stepped down as president of MDI Biological Laboratory at the end of his second term in 2018 to focus his efforts on growing Revidia Therapeutics and advancing their drug candidate into clinical trials.